NeurologyBiogen
Biogen and Eisai Report Phase 2b BAN2401 Results for Lecanemab in Alzheimer's Disease
BMI
Biotechnology Media Insights
Editorial Team · November 25, 2023
Biogen and Eisai announce Phase 2b trial results showing lecanemab significantly reduces amyloid plaques and slows clinical decline in early Alzheimer's disease.
Biogen and Eisai today announced Phase 2b trial results for lecanemab in patients with early Alzheimer's disease. The trial demonstrated a significant reduction in amyloid plaques and a slowing of clinical decline compared to placebo at 18 months. These results supported the advancement of lecanemab into Phase 3 development.
BMI
Biotechnology Media Insights
Published by Biotechnology Media Insights — your trusted source for pharmaceutical, biotech, and life sciences news.